Neurocrine Biosciences, Inc. (NASDAQ:NBIX)‘s stock had its “outperform” rating reiterated by equities research analysts at Robert W. Baird in a research report issued on Thursday. They presently have a $66.00 price objective on the stock. Robert W. Baird’s price target suggests a potential upside of 16.20% from the stock’s current price.

A number of other analysts also recently issued reports on NBIX. Cowen and Company restated an “outperform” rating and set a $65.00 price objective (up previously from $60.00) on shares of Neurocrine Biosciences in a report on Wednesday, August 9th. Needham & Company LLC restated a “buy” rating and set a $58.00 price objective on shares of Neurocrine Biosciences in a report on Sunday. Piper Jaffray Companies set a $68.00 price objective on shares of Neurocrine Biosciences and gave the stock a “buy” rating in a report on Wednesday, May 24th. BMO Capital Markets raised their price objective on shares of Neurocrine Biosciences from $75.00 to $84.00 and gave the stock an “outperform” rating in a report on Friday, August 4th. Finally, BidaskClub upgraded shares of Neurocrine Biosciences from a “hold” rating to a “buy” rating in a report on Wednesday, August 9th. Two equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. Neurocrine Biosciences has a consensus rating of “Buy” and a consensus price target of $68.25.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings data on Thursday, August 3rd. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.01). The company had revenue of $6.34 million for the quarter, compared to analyst estimates of $0.61 million. During the same period in the previous year, the business earned ($0.46) EPS.

COPYRIGHT VIOLATION WARNING: “Neurocrine Biosciences, Inc. (NBIX) Receives Outperform Rating from Robert W. Baird” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.americanbankingnews.com/2017/09/21/neurocrine-biosciences-inc-nbix-receives-outperform-rating-from-robert-w-baird.html.

In related news, insider Christopher Flint Obrien sold 8,734 shares of the business’s stock in a transaction that occurred on Thursday, July 27th. The shares were sold at an average price of $50.00, for a total transaction of $436,700.00. Following the completion of the transaction, the insider now owns 57,707 shares of the company’s stock, valued at $2,885,350. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Haig P. Bozigian sold 22,500 shares of the business’s stock in a transaction that occurred on Friday, August 4th. The shares were sold at an average price of $50.00, for a total transaction of $1,125,000.00. Following the transaction, the insider now directly owns 154,601 shares of the company’s stock, valued at approximately $7,730,050. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 125,655 shares of company stock valued at $7,018,148. 4.80% of the stock is owned by corporate insiders.

A number of large investors have recently modified their holdings of the stock. Teacher Retirement System of Texas grew its stake in Neurocrine Biosciences by 0.8% during the second quarter. Teacher Retirement System of Texas now owns 6,966 shares of the company’s stock valued at $320,000 after acquiring an additional 57 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in Neurocrine Biosciences by 7.8% during the second quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock valued at $123,000 after acquiring an additional 193 shares in the last quarter. Utah Retirement Systems grew its stake in Neurocrine Biosciences by 1.9% during the second quarter. Utah Retirement Systems now owns 16,000 shares of the company’s stock valued at $736,000 after acquiring an additional 300 shares in the last quarter. Schroder Investment Management Group grew its stake in Neurocrine Biosciences by 1.7% during the first quarter. Schroder Investment Management Group now owns 20,496 shares of the company’s stock valued at $856,000 after acquiring an additional 335 shares in the last quarter. Finally, Nuveen Asset Management LLC grew its stake in Neurocrine Biosciences by 5.6% during the first quarter. Nuveen Asset Management LLC now owns 14,464 shares of the company’s stock valued at $626,000 after acquiring an additional 763 shares in the last quarter.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Analyst Recommendations for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.